Vectura, Incannex to advance IHL-216A for treatment of traumatic brain injury

New Drug Applications |  News | 0 Comment | 22 Jun, 2021

Vectura Group has signed an agreement with Australia-based Incannex Healthcare to provide pre-clinical development servi...Read more

RSF Bio enters worldwide license agreement with Sanofi for cardiovascular drug

New Drug Applications |  News | 0 Comment | 18 Jun, 2021

Rancho Santa Fe Bio, Inc. (RSF Bio), a San Diego, California-based clinical-stage cardiovascular platform company, annou...Read more

Merck to commercialize Type 2 Diabetes drug in six growth markets

New Drug Applications |  News | 0 Comment | 04 May, 2021

Merck has signed a collaboration agreement with Janssen Pharmaceuticals NV around the commercialization of INVOKANA...Read more

S. Korea's Peptron licenses global development of ADCs for cancer treatment

New Drug Applications |  News | 0 Comment | 19 Apr, 2021

Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a China-based pharmaceutical company f...Read more

BioVersys receives €20M in EU financing to support new antibiotics development

New Drug Applications |  News | 0 Comment | 14 Apr, 2021

The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments ...Read more

SK Biopharma seizures/epilepsy drug to launch in Europe

New Drug Applications |  News | 0 Comment | 05 Apr, 2021

SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced that cenobamate received marketi...Read more

Australian oncology drug Paxalisib receives rights to develop and commercialize in China

New Drug Applications |  News | 0 Comment | 05 Apr, 2021

Sydney-based Kazia Therapeutics Limited, an oncology-focused drug development company announced that it has entered into...Read more

Astellas launches XOSPATA (gilteritinib) in Singapore to treat adult Leukaemia patients

New Drug Applications |  News | 0 Comment | 31 Mar, 2021

Astellas Pharma Inc. announced on March 31, 2021, that XOSPATA® (generic name: gilteritinib) is now available for pr...Read more

Eisai's Anti Cancer agent Lenvatinib-Pembrolizumab combo receives EMA in Japan

New Drug Applications |  News | 0 Comment | 30 Mar, 2021

Eisai Co., Ltd. announced on March 30, 2021 that the European Medicines Agency (EMA) has confirmed it has acce...Read more

EirGenix's proposed Biosimilar 'Trastuzumab' shows positive Ph 3 results

New Drug Applications |  News | 0 Comment | 25 Mar, 2021

EirGenix, Inc. announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimi...Read more

Eisai Medicine Innovation Technology Solutions to launch in Japan

New Drug Applications |  News | 0 Comment | 22 Mar, 2021

Japanese firm Eisai Co., Ltd. as part of its strategic investment to realize its medium-term management plan, EWAY ...Read more

Eisai's anti-Insomnia drug Dayvigo (Lemborexant) approved in Hong Kong

New Drug Applications |  News | 0 Comment | 01 Mar, 2021

Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-hou...Read more

Eisai launches Parkinson's disease treatment Equfina in South Korea

New Drug Applications |  News | 0 Comment | 02 Feb, 2021

Eisai Co., Ltd. has announced that Eisai Korea Inc., (Eisai's subsidiary in South Korea) has launched the Parkinson's di...Read more

Korean firms repurpose FDA-approved drug for rheumatoid arthritis treatment

New Drug Applications |  News | 0 Comment | 11 Jan, 2021

Standigm Inc, an artificial intelligence (AI)-based drug discovery company and SK Chemicals Co, Ltd, a life science and ...Read more

Chugai’s Enspryng becomes first approved medicine for NMOSD in Taiwan

New Drug Applications |  News | 0 Comment | 11 Dec, 2020

Chugai Pharmaceutical Co., Ltd. announced that Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obta...Read more

AstraZeneca's Forxiga approved in Japan for chronic heart failure

New Drug Applications |  News | 0 Comment | 02 Dec, 2020

AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chro...Read more

Gilead, Eisai launch rheumatoid arthritis drug in Japan

New Drug Applications |  News | 0 Comment | 19 Nov, 2020

Gilead Sciences K.K. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Luc Hermans) and Eisai Co.,...Read more

Enhancing Survival of HCC Patients in The New Era - A Multi-disciplinary Team Approach

New Drug Applications |  Company results | 0 Comment | 13 Nov, 2020

Singapore's Health Sciences Authority (HSA) recently approved an immunotherapy regimen (Tecentriq + Avastin) t...Read more